AppYea, Inc. (APYP) Análisis de Acciones
Solo con fines informativos. No es asesoramiento financiero. Analysis by Sedat Aydin, Founder & Editor-in-Chief | AI-powered analysis. Data sourced from SEC filings and institutional-grade financial providers. Editorially reviewed. Not financial advice.
APYP representa a AppYea, Inc., una empresa del sector Technology con un precio de $0.02 (capitalización de mercado 13M). La acción obtiene una puntuación de 50/100, una calificación moderada basada en 9 KPI cuantitativos.
Ultimo analisis: 15 mar 2026Perfil Tecnológico y Posición Competitiva de AppYea, Inc. (APYP)
AppYea, Inc. develops and patents digital health solutions for sleep apnea and snoring, focusing on sensor-based monitoring and real-time detection. Their SleepX app and DreamIT wristband aim to provide accessible and convenient sleep disorder management, positioning them in the growing market for digital health technologies.
Tesis de Inversión
AppYea, Inc. presents a focused investment opportunity within the digital health sector, specifically targeting the sleep apnea and snoring market. With a market capitalization of $0.01 billion and a gross margin of 15.8%, the company is positioned to capitalize on the increasing demand for accessible and convenient sleep monitoring and treatment solutions. Key value drivers include the continued development and refinement of their SleepX and DreamIT product lines, expansion into new markets, and potential partnerships with healthcare providers. The company's low beta of 0.11 suggests relatively low volatility compared to the broader market. However, investors should be aware of the risks associated with investing in OTC-listed companies and the competitive landscape of the digital health market.
Basado en las finanzas de FMP y el análisis cuantitativo
Puntos clave
- Market capitalization of $0.01 billion, reflecting its current valuation in the OTC market.
- Gross margin of 15.8%, indicating the profitability of its products before operating expenses.
- Free cash flow of $-0.00B, highlighting the need for careful cash management and potential future financing.
- Beta of 0.11, suggesting lower volatility compared to the overall market.
- Focus on the digital health market for sleep apnea and snoring, addressing a significant and growing health concern.
Fortalezas
- Proprietary technology for sleep monitoring and treatment.
- Integrated solution combining app and wearable device.
- Focus on the growing market for digital health solutions.
- Low beta indicating lower volatility.
Debilidades
- Limited financial resources.
- Small number of employees.
- Dependence on single product line.
- OTC listing presents liquidity and regulatory challenges.
Catalizadores
- Upcoming: Potential partnerships with healthcare providers and sleep clinics.
- Ongoing: Continued development and refinement of SleepX and DreamIT product lines.
- Ongoing: Expansion into new geographic markets.
- Ongoing: Increased adoption of telehealth and remote patient monitoring.
Riesgos
- Potential: Competition from established medical device companies.
- Potential: Technological obsolescence.
- Ongoing: Limited financial resources.
- Ongoing: OTC listing presents liquidity and regulatory challenges.
- Potential: Regulatory changes in the healthcare industry.
Oportunidades de crecimiento
- Expansion into New Markets: AppYea can expand its market reach beyond its current base by targeting new geographic regions and demographic segments. The global market for sleep apnea devices is projected to reach billions of dollars, offering significant growth potential for AppYea's SleepX and DreamIT products. Timeline: Ongoing.
- Strategic Partnerships: Collaborating with healthcare providers, sleep clinics, and insurance companies can accelerate adoption of AppYea's solutions and increase market penetration. Partnerships can provide access to established distribution channels and patient networks. Timeline: Ongoing.
- Product Innovation: Continuous innovation and development of new features for the SleepX and DreamIT product lines can enhance their value proposition and attract new customers. This includes incorporating advanced sensor technologies, AI-powered analytics, and personalized treatment plans. Timeline: Ongoing.
- Direct-to-Consumer Marketing: Implementing targeted marketing campaigns to reach consumers directly through online channels, social media, and digital advertising can increase brand awareness and drive sales. This approach allows AppYea to bypass traditional healthcare channels and reach a wider audience. Timeline: Ongoing.
- Integration with Telehealth Platforms: Integrating AppYea's solutions with telehealth platforms can provide remote monitoring and treatment options for patients with sleep apnea and snoring. This integration can enhance patient engagement and improve treatment outcomes. Timeline: Ongoing.
Oportunidades
- Expansion into new geographic markets.
- Strategic partnerships with healthcare providers.
- Development of new features and products.
- Increased adoption of telehealth and remote patient monitoring.
Amenazas
- Competition from established medical device companies.
- Technological obsolescence.
- Regulatory changes in the healthcare industry.
- Economic downturn affecting consumer spending.
Ventajas competitivas
- Proprietary Algorithms: Unique algorithms for monitoring breathing and detecting snoring/sleep apnea events.
- Patented Technology: Designs and patents for sensor monitoring and software solutions.
- Integrated Solution: Combination of smartphone application and wearable device for comprehensive sleep monitoring and treatment.
Acerca de APYP
Founded in 2012 and based in Rehovot, Israel, AppYea, Inc. operates as a digital health company focused on designing, patenting, and producing sensor monitoring and software solutions for snoring and sleep apnea. The company's core product offerings include the SleepX App and DreamIT wristband. The SleepX App is a smartphone application that employs unique algorithms to monitor breathing and detect snoring events in real time. Complementing the app, the DreamIT wristband features various sensors and interfaces with the SleepX App to provide treatment for snoring. AppYea also offers SleepX PRO, an application designed to monitor breathing and detect sleep apnea incidents, and DreamIT PRO, a wristband that interfaces with the SleepX PRO app for sleep apnea treatment. AppYea aims to provide accessible and convenient solutions for individuals suffering from sleep-related breathing disorders, leveraging technology to improve sleep quality and overall health.
Qué hacen
- Designs and patents sensor monitoring solutions.
- Develops software for snoring and sleep apnea detection.
- Produces the SleepX App for real-time snoring monitoring.
- Manufactures the DreamIT wristband for snoring treatment.
- Offers SleepX PRO for sleep apnea detection.
- Provides DreamIT PRO for sleep apnea treatment.
Modelo de Negocio
- Develops and sells sensor-based monitoring devices (DreamIT wristband).
- Offers smartphone applications (SleepX App, SleepX PRO) for sleep monitoring and treatment.
- Generates revenue through direct sales to consumers.
- Potential for future revenue through partnerships with healthcare providers and insurance companies.
Contexto de la Industria
AppYea, Inc. operates within the rapidly expanding digital health market, specifically targeting sleep apnea and snoring solutions. The industry is characterized by increasing adoption of telehealth and remote patient monitoring technologies. The competitive landscape includes established medical device companies, as well as emerging digital health startups. AppYea's focus on sensor-based monitoring and smartphone integration positions it to capitalize on the growing demand for accessible and convenient sleep disorder management.
Clientes Clave
- Individuals suffering from snoring.
- Individuals suffering from sleep apnea.
- Healthcare providers seeking remote patient monitoring solutions.
- Sleep clinics and sleep disorder centers.
Finanzas
Gráfico e información
Precio de la acción de AppYea, Inc. (APYP): $0.02 (+0.00, +20.67%)
Últimas noticias
-
Stocks That Hit 52-Week Lows On Monday
· 10 feb 2020
-
Stocks That Hit 52-Week Lows On Tuesday
· 3 dic 2019
-
Stocks That Hit 52-Week Lows On Wednesday
· 9 oct 2019
Consenso de analistas
Calificación de Consenso
Recomendaciones agregadas de Compra/Mantener/Vender de Benzinga, Yahoo Finance y Finnhub para APYP.
Objetivos de Precios
Análisis del precio objetivo de Wall Street para APYP.
MoonshotScore
¿Qué significa esta puntuación?
El MoonshotScore califica el potencial de crecimiento de APYP en una escala de 0 a 100 en múltiples factores, incluyendo innovación, disrupción del mercado, salud financiera e impulso.
Liderazgo: Yakir Abady
CEO
Yakir Abady serves as the CEO of AppYea, Inc. His background includes experience in managing and leading technology-driven companies. He is responsible for overseeing the company's strategic direction, product development, and overall operations. His leadership is focused on driving innovation and growth in the digital health market, particularly in the area of sleep apnea and snoring solutions.
Historial: Under Yakir Abady's leadership, AppYea, Inc. has focused on developing and commercializing its SleepX and DreamIT product lines. Key milestones include securing patents for its sensor monitoring technology and expanding its market reach through online channels. He is currently focused on securing partnerships to expand market reach.
Información del mercado OTC de APYP
The OTC Other tier represents the lowest tier of the OTC market, indicating that AppYea, Inc. may not meet the minimum financial or reporting requirements for higher tiers like OTCQB or OTCQX. Companies in this tier often have limited operating history, minimal assets, or may be undergoing financial distress. Investing in OTC Other stocks carries significant risks due to the lack of regulatory oversight and transparency compared to NYSE or NASDAQ-listed companies. Investors should exercise extreme caution and conduct thorough due diligence before investing in OTC Other securities.
- Nivel OTC: OTC Other
- Estado de divulgación: Unknown
- Limited Liquidity: Low trading volume and wide bid-ask spreads can make it difficult to buy or sell shares.
- Lack of Transparency: Limited financial reporting and regulatory oversight increase the risk of fraud and manipulation.
- Financial Instability: Companies in the OTC Other tier may be financially distressed or have limited operating history.
- Dilution Risk: Frequent stock dilutions can significantly reduce the value of existing shares.
- Regulatory Scrutiny: OTC-listed companies are subject to less regulatory scrutiny than exchange-listed companies.
- Verify the company's financial statements and SEC filings (if any).
- Research the background and experience of the company's management team.
- Assess the company's business model and competitive landscape.
- Evaluate the company's capital structure and potential for dilution.
- Review the company's legal and regulatory compliance.
- Check for any red flags or warning signs in the company's history.
- Understand the risks associated with investing in OTC-listed companies.
- Patents for sensor monitoring technology.
- Development of SleepX and DreamIT product lines.
- Focus on the growing market for digital health solutions.
APYP Preguntas Frecuentes sobre Acciones de Technology
¿Cuáles son los factores clave para evaluar APYP?
AppYea, Inc. (APYP) actualmente tiene una puntuación IA de 50/100, indicando puntuación moderada. Fortaleza clave: Proprietary technology for sleep monitoring and treatment.. Riesgo principal a monitorear: Potential: Competition from established medical device companies.. Esto no es asesoramiento financiero.
¿Qué es el MoonshotScore de APYP?
APYP actualmente puntúa 50/100 (Grado C) en el MoonshotScore, lo que sugiere calificación moderada. La puntuación evalúa el potencial de crecimiento, la salud financiera, el impulso del mercado y los factores de riesgo en 9 KPIs cuantitativos. Se recalcula diariamente con los últimos datos del mercado. Esta puntuación es solo informativa.
¿Con qué frecuencia se actualizan los datos de APYP?
Los precios de APYP se actualizan en tiempo real durante el horario del mercado estadounidense (9:30-16:00 ET, días laborables). Los fundamentales se actualizan después de los informes trimestrales o anuales. Las calificaciones de analistas y las perspectivas de IA se actualizan diariamente. Las noticias se agregan continuamente de fuentes financieras.
¿Qué dicen los analistas sobre APYP?
La cobertura de analistas para APYP incluye calificaciones de consenso (compra, mantener, venta), objetivos de precio a 12 meses y estimaciones de ganancias de las principales firmas de investigación. Consulte la sección de Consenso de Analistas en esta página.
¿Cuáles son los riesgos de invertir en APYP?
Las categorías de riesgo para APYP incluyen riesgo de mercado, riesgo específico de la empresa (gestión, competencia), riesgo financiero (deuda, consumo de efectivo) y riesgo macroeconómico (tasas, inflación). Un riesgo clave identificado: Potential: Competition from established medical device companies.. Un beta superior a 1,0 indica mayor volatilidad que el S&P 500. Revise la sección de Factores de Riesgo en esta página. Todas las inversiones conllevan riesgo de pérdida.
¿Cuál es la relación P/E de APYP?
La relación P/E para APYP compara el precio actual de la acción con sus ganancias por acción. Un P/E más alto puede indicar expectativas de crecimiento, mientras que un P/E más bajo puede sugerir valor. Consulte la pestaña de Financieros para métricas actuales.
¿Está APYP sobrevalorada o infravalorada?
Determinar si AppYea, Inc. (APYP) está sobrevalorada o infravalorada requiere examinar múltiples métricas. Compare los ratios de valoración (P/E, P/S, EV/EBITDA) con pares del sector. Esto no es asesoramiento financiero.
¿Cuál es el rendimiento por dividendo de APYP?
AppYea, Inc. (APYP) actualmente no paga un dividendo regular, o los datos de rendimiento no están disponibles. Consulte la pestaña de Financieros para información actual.
Descargo de responsabilidad: Este contenido es solo para fines informativos y no constituye asesoramiento de inversión. Siempre haga su propia investigación y consulte a un asesor financiero.
Recursos Oficiales
Datos proporcionados solo con fines informativos.
- Information is based on available data as of 2026-03-15.
- OTC market data may be limited or unreliable.
- Analyst coverage may be limited due to the company's size and OTC listing.